ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Nandrolone Experiences
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="DS3" data-source="post: 194628" data-attributes="member: 18514"><p>Limiting estrogen via aromatase inhibitors or by using a non-aromatizing hormone as a base would likely produce neurotoxic effects given the neuroprotective nature of estrogen. That much is true. However, neurotoxic effects of Anavar is not demonstrated in TRT patients or patients with cachexia. Anavar, being a DHT-derived drug, does not possess the ability to aromatize. Why would this be? Patients using oxandrolone in clinical settings are taking it as an adjunct therapy to testosterone; they would already have sufficient estrogen in their system.</p><p></p><p>Aside from animal models demonstrating neurotoxic effects of nandrolone, there are no human studies studying this phenomenon. The limitations of these animal models are that they did not administer testosterone alongside the nandrolone. If nandrolone does indeed produce neurotoxic effects in TRT patients, it wouldn’t be due to a lack of aromatization; the patient would already have sufficient estradiol in his system. There would have to be another mechanism(s) causing this effects.</p></blockquote><p></p>
[QUOTE="DS3, post: 194628, member: 18514"] Limiting estrogen via aromatase inhibitors or by using a non-aromatizing hormone as a base would likely produce neurotoxic effects given the neuroprotective nature of estrogen. That much is true. However, neurotoxic effects of Anavar is not demonstrated in TRT patients or patients with cachexia. Anavar, being a DHT-derived drug, does not possess the ability to aromatize. Why would this be? Patients using oxandrolone in clinical settings are taking it as an adjunct therapy to testosterone; they would already have sufficient estrogen in their system. Aside from animal models demonstrating neurotoxic effects of nandrolone, there are no human studies studying this phenomenon. The limitations of these animal models are that they did not administer testosterone alongside the nandrolone. If nandrolone does indeed produce neurotoxic effects in TRT patients, it wouldn’t be due to a lack of aromatization; the patient would already have sufficient estradiol in his system. There would have to be another mechanism(s) causing this effects. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Nandrolone Experiences
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top